Treatment Satisfaction Research Articles

Intravaginal devices for running-induced urinary incontinence symptoms in females: a study protocol.

Exercise-induced urinary incontinence (UI) can hinder physical activity, particularly in women engaging in high-impact activities. This condition is linked to reduced passive support of the urethra and bladder. Intravaginal devices that support pelvic structures may offer a solution, but high-quality evidence is lacking. The study is an assessor-blind randomised controlled trial. Primary outcomes include frequency and amount of urine leakage during running over a 2-week period, Patient Global Impression of Improvement, treatment satisfaction, and the International Consultation on Incontinence Questionnaire-Urinary Incontinence Short Form, measured at baseline and after a 10-week intervention. Secondary outcomes include adherence and unintended effects. A subset of participants will be invited to a laboratory-based assessment at baseline and follow-up involving pelvic floor morphometry and function to explore the mechanisms through which the interventions may be effective. We aim to recruit 90 runners aged ≥18 years, with female-typical pelvic anatomy, who report running-induced UI. After 2 weeks of leakage tracking without any intervention, participants will be randomly assigned to a 10-week pessary, tampon, or control intervention (1:1:1 ratio). Follow-up assessments will be performed at 11-12 and 16 weeks. Between- and within-group differences will be evaluated with general linear models using an intent-to-treat approach. This study is registered (ClinicalTrials.gov identifier: NCT05773378), has been approved by the local Institutional Research Ethics Board, and follows the Declaration of Helsinki. Results will be published in peer-reviewed journals, shared with clinicians and participants, and disseminated publicly.

Automated Insulin Delivery in Pregnancies Complicated by Type 1 Diabetes.

Automated insulin delivery (AID) systems adapt insulin delivery via a predictive algorithm integrated with continuous glucose monitoring and an insulin pump. Automated insulin delivery has become standard of care for glycemic management of people with type 1 diabetes (T1D) outside pregnancy, leading to improvements in time in range, with lower risk for hypoglycemia and improved treatment satisfaction. The use of AID facilitates optimal preconception care, thus more women of reproductive age are becoming pregnant while using AID. The effectiveness and safety in pregnant populations of using AID systems with algorithms for non-pregnant populations may be impacted by requirements for lower glucose targets and existence of increased insulin resistance during gestation. The CamAPS FX is the only AID system approved for use in pregnancy. A large randomized controlled trial (RCT) with this AID system demonstrated a 10.5% increase in time in pregnancy range (an additional 2.5 hours/day) compared with standard insulin therapy in pregnant women with T1D with a baseline glycated hemoglobin A1c (HbA1c) ≥48 mmol/mol (6.5%). A RCT of AID not approved for use in pregnancy (MiniMed 780G) has also demonstrated some benefits of AID compared with standard insulin therapy with improved time in pregnancy range overnight (24 minutes), less hypoglycemia, and improved treatment satisfaction. There is also increasing evidence that AID can be safely continued during delivery and postpartum, while maintaining glycemic goals with lower risk for hypoglycemia. More AID systems are needed with flexible glucose targets in the pregnancy range and possibly with algorithms that better adapt to changing insulin requirements. More evidence is needed on the impact of AID on maternal and neonatal outcomes. We review the current evidence on the use of AID in pregnancy and postpartum.

Correlates of Treatment Satisfaction among Adults Convicted of Sex Offenses.

Treatment satisfaction and post-treatment factors have not received focus in research on the efficacy of sex offender treatment. We aim to describe factors that are associated with treatment satisfaction and how having satisfaction with sex offender treatment is related to future health and protective factors. We solicited responses via an anonymous self-administered survey from 718 adults in the United States who were required to register on a sex offender registry. Being older, a person of color, and not sentenced to prison were associated with higher odds of treatment satisfaction. Those convicted of rape offenses had higher odds of treatment satisfaction than respondents with other types of sexual offenses. A significant relationship was found between treatment satisfaction and being in a committed relationship, being in good mental and physical health, and being self-employed. The results suggest that satisfaction with treatment is a good predictor of treatment benefits.

Effect of aromatherapy with lemongrass (Cymbopogon citratus) on the anxiety of patients undergoing scaling and root planning: a randomized clinical trial

BackgroundAnxiety is one of the most common factors that prevent people from going to a dentist. Therefore, finding a solution to better control stress has been an important issue in recent studies. Lemongrass positively affects the prevention of dental anxiety. The literature has shown that aromatherapy may regulate hemodynamic factors in patients. This study investigated the effects of the aroma of lemongrass on anxiety levels and hemodynamic factors during nonsurgical periodontal treatment.MethodsThirty-eight patients were divided into two groups. First, the patients were asked to complete the Spielberger questionnaire to measure their level of dental anxiety. Blood pressure, heart rate, oxygen saturation, pain and satisfaction with treatment were evaluated. In the case group, nonsurgical periodontal therapy was performed while the patient inhaled the aroma of the lemongrass. Scaling was performed without intervention in the control group. The patients were then asked to complete the questionnaire again, and all the variables mentioned were remeasured.ResultsAromatherapy with lemongrass caused significant reductions in the systolic and diastolic blood pressure values, heart rate, and anxiety scores of patients. On the other hand, the differences in blood oxygen saturation changes, amount of pain and treatment satisfaction were insignificant between the two groups.ConclusionInhalation of lemongrass essential oil appears beneficial for reducing anxiety and associated hemodynamic changes. Thus, aromatherapy with lemongrass may alleviate dental patients’ anxiety.Trial registrationhttps://irct.behdasht.gov.ir/ IRCT20230615058492N2, 21/02/2024.

Knowledge and attitudes of Dutch psychiatry residents towards anorexia nervosa

BackgroundStigma significantly hinders treatment seeking, adherence to treatment, referrals, and can prolong recovery, while increasing the risk of relapse due to social exclusion and stress. Stigmatizing attitudes towards anorexia nervosa are widespread, and not only held by the general public, but also by professionals.ObjectiveAs stigmatizing attitudes towards mental disorders often develop early during education and training, the study’s objective was to investigate stigmatizing attitudes towards anorexia nervosa among Dutch psychiatry residents, as well as their mental health literacy.MethodsIn this pilot study, Dutch psychiatry residents (N = 61) were surveyed, with a 49% response rate, using a comprehensive questionnaire that included nine parts, covering multiple stigma domains, disease prestige, knowledge, and professional training.ResultsAnorexia nervosa was ranked 18th in disease prestige with a mean score of 6.23. Although most stigmatizing attitudes were not widely endorsed by psychiatry residents, there were a few notable exceptions, especially attitudes related to blame, fragility and social distance. They characterized patients as insecure, controlling, sad, and defensive, and reported feeling worried, incompetent, pessimistic and anxious when dealing with patients with anorexia nervosa. Only 37% felt confident in diagnosing anorexia nervosa.ConclusionThere is a critical need for further research on the social value ranking of psychiatric disorders and the development of a comprehensive stigma scale, as well as targeted educational interventions. Addressing stigma through focused training programs could lead to better patient outcomes, improved treatment satisfaction, and reduced barriers to care for individuals with anorexia nervosa.

A Multicenter Single-Arm Study of Switching to Ferric Citrate Hydrate for Iron Deficiency Anemia in Patients Intolerant to Oral Iron: RIO-SWITCH.

Treatment interruptions due to adverse drug reactions (ADRs) are common in iron deficiency anemia (IDA). We evaluated medication completion rates and quality of life (QoL) changes in patients with IDA after starting ferric citrate hydrate (FCH) treatment. This multicenter, open-label, uncontrolled, single-arm comparative study included 30 Japanese female patients with IDA who experienced nausea and/or vomiting (N/V) with previous oral iron preparations. Patients received FCH 500mg orally daily (< 1000mg/day). Those with hemoglobin levels ≥ 11.0g/dl completed the study at week 4; others continued until week 8. The primary endpoint was medication completion rate. Secondary endpoints included medication compliance rate, treatment satisfaction scores, and QoL scores and changes. Thirty patients initiated and completed treatment; 24 reached ≥ 11.0g/dl hemoglobin at week 4 and ended treatment, while 6 continued until week 8. The medication compliance rate was 93.92% ± 8.11% (mean ± standard deviation [SD]), and the completion rate was 100.0% (95% confidence interval 88.4-100.0%). Questionnaire findings revealed that the most severe nausea score decreased from 5.7 ± 2.4 to 1.7 ± 2.1 (mean ± SD), N/V incidence decreased from 100.0 to 63.3%, and patients reporting that N/V did not interfere with daily life increased from 6.7 to 52.6% following the switch to FCH. Twenty-four patients (80.0%) reported a satisfactory experience with FCH versus their previous oral iron preparation. Scores for all eight subscales of the Short-Form 36-Item Health Survey v2 improved, with significant increases in six. Nine ADR events occurred in six patients (20.0%), including nausea in three (10.0%); none were serious or resulted in treatment discontinuation. FCH treatment exhibited a satisfactory medication completion rate in patients with IDA. Switching to FCH reduced N/V incidence and improved N/V and QoL severity compared with previous oral iron preparations. jRCTs031210634. Registration date: March 01, 2022.

Development of the Dentofacial Appearance Perception Scale: Validity and reliability study.

Concerns about the appearance of teeth and mouth, which play a key role in communication and first impressions, are natural to some extent. However, excessive concern over these areas should raise suspicion of body dysmorphic disorder (BDD). The use of a validated and standardized screening tool in dental settings may improve the identification of BDD. This study aims to develop a validated tool to alert dentists to potential BDD cases among patients seeking cosmetic dental procedures. The research team conducted a literature review and initially created a pool of 26 items. A qualitative evaluation of the scale items was conducted by the researchers, during which each question was analyzed and discussed, resulting in the reduction of the number of items to 21. During the content validity process, 2 items were removed using the Lawshe technique, and 3 items were excluded during the exploratory factor analysis, finalizing the scale with 16 items. Participants from Izmir Democracy University's Dental Clinic were involved in the study. Both exploratory and confirmatory factor analyses were executed to affirm the scale's construct validity, and reliability was measured through Cronbach alpha. Statistical processing was done using Statistical Package for the Social Sciences and JASP software. After rigorous item analysis and exploratory factor analyses across 2 testing rounds, a finalized version of the questionnaire emerged. A total of 193 individuals voluntarily participated in the study, with 56.67% being female. The participants had an average age of 29.53 years (min: 18, max: 65). Only individuals presenting to the university hospital dental clinic for cosmetic reasons were included in the study. The final version of the scale, comprising 16 items across 3 factors, demonstrated adequate validity and reliability. Factor analysis accounted for 53.72% of the variance, with the factors labeled as follows: "Impairment in Functionality," "Dental Appearance Satisfaction," and "Preoccupation." Confirmatory factor analysis supported the structural integrity of the scale, and overall reliability, as indicated by a Cronbach alpha of 0.90, confirmed its consistency. The Dental Appearance Perception Scale is a reliable and valid tool with the potential to screen for BDD risks and enhance treatment satisfaction in dental settings.

Patient perspectives on rheumatic and musculoskeletal diseases: insights from a large-scale survey.

Rheumatic and musculoskeletal diseases (RMD) are prevalent among Arabic-speaking patients in the Middle East and North Africa (MENA), yet their perspectives remain underexplored. This study examines patient experiences and perspectives. A cross-sectional survey was developed using pilot testing with clinimetric sensibility assessment to ensure clarity and relevance, and the Open-Source Metric for Measuring Arabic Narratives (OSMAN) to assess readability. The Checklist for Reporting Internet E-Surveys (CHERRIES) was used to enhance the quality of the survey. The survey was distributed via social media to Arabic-speaking patients with self-reported RMDs.Collected data included demographics, disease characteristics, medication use, treatment satisfaction factors, perceived causes, and patient concerns. Of the 1050 responses received, 456 were complete and included in the analysis. Most respondents were female (81.4%) and between the ages of 25 and 44 (63.4%). The most frequently reported diseases were systemic lupus erythematosus, rheumatoid arthritis, and ankylosing spondylitis. Nearly all (97.1%) used medications within the previous three months, primarily hydroxychloroquine, glucocorticoids, and biologics. Key factors influencing treatment satisfaction were pain relief, laboratory result discussions, sleep quality, and mood improvement. Patients perceived immune system abnormalities (76.5%), psychological factors (54.8%), and genetics (41.7%) as primary disease causes. Main concerns included fear of disease complications, adverse drug reactions, and being a burden to others. Rheumatologists and internet search engines were the primary sources of information for patients. Most avoided alternative medicine, while 33.3% used it. This survey is the first and largest in the MENA region, providing valuable insights into patient perspectives on RMD. It highlights the need for holistic management, enhanced education, and supportive services to improve quality of life. Key Points • The most commonly perceived causes of rheumatic and musculoskeletal diseases among patients with RMD were immune system abnormalities, psychological factors, genetic/hereditary influences, and envy. • Patients' top concerns included fear of future complications, adverse drug reactions, becoming a burden to others, physical disability, and issues related to marriage and childbirth. • Key factors influencing treatment satisfaction included pain relief, discussions of laboratory results, sleep quality, and mood improvement. • Approximately one-third of patients had consulted practitioners of complementary and alternative medicine.

Correlation of Patient Satisfaction, Treatment Duration, and Temporization Material in Implant-Supported Full Mouth Rehabilitation: An Institution-Based Retrospective Analysis

Full mouth rehabilitation is a comprehensive treatment and hence requires longer duration along with patient co-operation and operator skill. Time period of one year from 2019 to 2020, records of 8900 patients from the Digital Information Archiving Software (DIAS) records of Saveetha Dental College and Hospital, India. 66 patients who underwent implant supported full mouth rehabilitation were included in this retrospective study. The data on the treatment duration, patient satisfaction, type of temporary teeth and change in vertical dimension was collected. The data censored was collected by recalling the patient and reviewing. Data was statistically analysed using Pearson's correlation and association was evaluated using chi-square analysis to quantify the association between patient satisfaction and duration of treatment and the type of temporisation. The correlation between patient satisfaction and treatment duration was found to be insignificant (p&gt;0.05) and the satisfaction was higher in the patients in whom the duration of treatment was shorter compared to the others. The association between patient satisfaction and type of temporisation was statistically significant (p&gt;0.05), however the patient satisfaction was higher in the patients who received CAD CAM temporary teeth compared to those who received conventional temporary teeth. From the available data it was observed the duration of the treatment plays a secondary role in relation to patient satisfaction in treatment of full mouth rehabilitation cases. The quality of treatment and decisiveness in providing definitive care with respect to treatment needs gives a better patient satisfaction.

The Expanding Therapeutic Potential of Deucravacitinib Beyond Psoriasis: A Narrative Review

Deucravacitinib is an allosteric, selective tyrosine kinase 2 (TYK2) inhibitor that has demonstrated significant efficacy in the treatment of psoriasis. TYK2, a member of the Janus kinase (JAK) family, plays a critical role in intracellular signaling pathways for pro-inflammatory cytokines. Unlike traditional JAK inhibitors, which target active domains, deucravacitinib selectively binds to the pseudokinase domain of TYK2. This binding induces a conformational change that locks the enzyme in an inactive state, ensuring superior selectivity for TYK2 over JAK 1/2/3. This unique mechanism specifically inhibits key pro-inflammatory cytokines, including IL-12, IL-23, and type I interferons, critical in the pathogenesis of psoriasis and other immune-mediated diseases. As a result, deucravacitinib represents a promising option for targeted therapy in immune-mediated diseases and may reduce adverse events commonly associated with broader immunosuppressive treatments. Furthermore, its oral administration offers a convenient alternative to injectable biologics, potentially improving patient adherence and treatment satisfaction. This review highlights recent studies suggesting that deucravacitinib may also have therapeutic benefits in psoriatic arthritis, palmoplantar pustulosis, systemic lupus erythematosus, Sjogren’s disease, and inflammatory bowel disease. Given its expanding therapeutic potential, deucravacitinib may provide a safer and more effective alternative to current therapies, offering a tailored approach to treatment.

Cutaneous T-cell lymphomas: a real-life experience of anticipated use of mogamulizumab in Italy.

Mogamulizumab is a humanized monoclonal antibody with enhanced antibody-dependent cell-mediated cytotoxicity that targets chemokine receptor type. Several clinical trials and real-life experiences confirmed the efficacy and safety profiles of mogamulizumab as second-line therapy and beyond, and the biochemical- and dermatology-specific quality of life and physical functioning, with high treatment satisfaction. Systemic drugs are usually used in patients with resistant or advanced forms of cutaneous T-cell lymphomas (especially mycosis fungoides) or with Sézary Syndrome, while early-stage mycosis fungoides can be managed at least initially with local treatments. The most recent Guidelines confirm this approach, but recommend also an anticipated use (starting from the second line) of new therapeutic agents in advanced skin lymphomas. In this report, we discuss eight cases of patients with mycosis fungoides or Sézary Syndrome successfully managed with an anticipated use of mogamulizumab in real-life clinical practice in Italy.

Psychometric properties of the Persian version of the treatment satisfaction questionnaire for medication (TSQM) among Iranian hypertensive patients.

This study aimed to evaluate the psychometric properties of the Persian version of the TSQM-14 in patients with hypertension in Iran. This cross-sectional study was conducted among hypertensive patients referred to primary healthcare centers in Kerman City between January and February 2021. Cronbach's alpha and total-item correlation were used to evaluate internal consistency, while the Intraclass Correlation Coefficient (ICC) was employed to assess test-retest reliability. Construct validity was examined using structural equation modeling (SEM), known-groups validity, and convergent validity. A total of 319 participants took part in the study, with a mean age of 56.7 years (SD = 13.0), and 57.7% (n = 184) were female. The Cronbach's alpha and ICC values of the TSQM-14 for the composite scales were 0.83 and 0.91, respectively, indicating good reliability. The SEM indices for TSQM-14 demonstrated adequate model fit, with χ² = 118.9 (P ≤ 0.001), CFI = 0.96, RMSEA = 0.07, TLI = 0.95, and NFI = 0.91. The mean (standard deviation (SD)) scores of the composite scale for patients in the uncontrolled group (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg) and the controlled group were 50.2 (SD = 6.6) and 47.6 (SD = 6.1), respectively (P = 0.021). Additionally, the Spearman correlation coefficient between the TSQM-14 scale and the MMAS-8 was 0.30 (P < 0.001), demonstrating a weak but significant correlation. This study demonstrated that the Persian version of the TSQM-14 has acceptable reliability, as well as construct and convergent validity, for assessing treatment satisfaction among hypertensive patients.

Treatment Utilisation and Satisfaction With Management in Individuals With Osteoarthritis and Metabolic Multimorbidity: A Cross-Sectional Multi-Country Study.

To compare treatment utilisation for osteoarthritis (OA) and satisfaction with OA management between individuals with and without comorbid metabolic conditions (e.g., diabetes, obesity, dyslipidaemia, hypertension). Secondary analysis of a cross-sectional international survey study (Italy, Russia, Sweden) on people ≥ 40years old with knee/hip OA. Metabolic comorbidity was self-reported. We used direct standardisation with prevalence ratios and mixed-effect models to estimate the associations between comorbidity with treatment utilisation and satisfaction (score 0-100). We analysed 401 individuals (48% Sweden, 28% Italy, 24% Russia; 53% with ≥ 1 metabolic condition). Those with and without comorbid metabolic conditions showed similar prevalence for first-line interventions (exercise, education, and weight management). Metabolically unhealthy individuals showed higher use of opioids (prevalence ratio [95% CI] 1.9 [1.3-2.4]), antidepressants (1.8 [1.1-2.5]), corticosteroid injections (1.4 [1.0-1.8]), and homoeopathic products (2.1 [1.2-3.0]). Satisfaction with care (adjusted difference: -3.9 [95% CI: -8.5 to 2.4]) and information received about treatments (-4.0 [-9.7 to 1.7]) were similar. While first-line OA interventions were similarly used, those with metabolic conditions relied more on second-line and non-recommended treatments, showing comparable satisfaction. More effort is needed to increase the adoption of lifestyle-focused treatments in OA and to minimise the use of less recommended options among individuals with metabolic comorbidities.

Tongxinshu capsules in the treatment of stable angina pectoris due to qi deficiency and blood stasis in coronary heart disease: A multicenter, randomized, double-blind, placebo-controlled trial.

Tongxinshu capsules in the treatment of stable angina pectoris due to qi deficiency and blood stasis in coronary heart disease: A multicenter, randomized, double-blind, placebo-controlled trial.

Cultural adaptation of a self-help app for grieving Syrian refugees in Switzerland. A feasibility and acceptability pilot-RCT.

Cultural adaptation of a self-help app for grieving Syrian refugees in Switzerland. A feasibility and acceptability pilot-RCT.

Lipid-Lowering Efficiency and Safety of Alirocumab 300 mg Using a 2-mL Autoinjector Device in Real-World Practice: The MARS Study.

Alirocumab is a fully human monoclonal antibody to proprotein convertase subtilisin kexin type 9 used for the reduction of low-density lipoprotein cholesterol (LDL-C) in high-risk patients not reaching their LDL-C target. Recently, a 2-mL prefilled autoinjector has been developed to support the monthly 300-mg dosing regimen with a single-injection administration. Monthly application of 300 mg AlirRocumab (Praluent®) using the 2-mL SYDNEY Device (MARS) is a non-interventional, open, prospective, multi-center cohort study conducted in Germany between 2021 and 2023 with an observational period of 12 weeks. Patients included had primary hypercholesterolemia (heterozygous familial or non-familial) or mixed dyslipidemia and confirmed vascular disease and other risk factors or confirmed familial heterozygous hypercholesterolemia. Primary objectives were to assess the effectiveness of the 2-mL SYDNEY autoinjector measured by the lipid-lowering effect of alirocumab and to document therapy satisfaction, patient adherence, and persistence. Secondary objectives were to assess safety (adverse events) and tolerability. A total of 146 patients were analyzed: 110 (75.3%) patients were proprotein convertase subtilisin kexin type 9 inhibitor naïve and 36 (24.7%) were pre-treated with a proprotein convertase subtilisin kexin type 9 inhibitor. Patient mean age was 65.6 years with a preponderance of male gender (59.6%). At 12 weeks, the LDL-C value had decreased by a median of 59.5 mg/dL (1.5 mmol/L) in naïve patients (median relative decrease: -52.0%). In the pre-treated group, the LDL-C value remained mainly unchanged (median slight numerical relative increase: 1.6%). Treatment satisfaction was rated similarly in both groups with most patients being satisfied/very satisfied and rating the injection as effective, safe, and easy to handle. Twenty-three adverse events in 13 patients (8.0%) were documented. Three patients experienced one serious adverse event each; for five patients, an adverse drug reaction was observed, although none was serious. The occurrence of adverse events was similar in both groups. Alirocumab 300 mg administered with the 2-mL SYDNEY autoinjector was safe and effective in lowering LDL-C after 12 weeks in a routine clinical setting in Germany. The treatment schedule was perceived to be beneficial with excellent device acceptance and satisfaction, potentially increasing patient adherence. Clinicaltrials.gov: NCT05129241.

EFFECTIVENESS OF CLEAR ORTHODONTIC ALIGNERS IN CORRECTING MALOCCLUSIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS.

EFFECTIVENESS OF CLEAR ORTHODONTIC ALIGNERS IN CORRECTING MALOCCLUSIONS: A SYSTEMATIC REVIEW AND META-ANALYSIS.

Evaluating Veterans' Preferences for Renal Denervation for Treatment of Difficult-to-Control Hypertension: A Single-Center Survey Study.

Catheter-based renal denervation (RDN) is a safe and effective alternative treatment for hypertension. However, data on patient preferences are limited. This study sought to delineate preferences for RDN among Veterans with difficult-to-control hypertension at an urban VA Medical Center with the goal of optimizing management and referral practices in hypertensive Veterans. Patients on 3+ antihypertensive medications and a measured creatinine < 2.5 mg/dL were identified from the pharmacy database. A total of 100 randomly selected patients were telephoned for the administration of a survey assessing patient preferences for RDN, expectations for RDN, as well as medication adherence using the Medication Adherence Report Scale (MARS-5). Additional chart review was performed to gather demographic and clinical data of survey respondents. A total of 51 Veterans completed the survey. While 29 (56.9%) Veterans indicated a preference against RDN, 22 (43.1%) indicated a preference for this procedure, and 33 (64.7%) expressed that if their blood pressure were uncontrolled, they would prefer RDN over additional medication. A history of congestive heart failure (p = 0.017) and lower MARS-5 score (p = 0.007) were associated with a preference for RDN. Age, reported medication side effects, and hypertension treatment satisfaction ratings were not associated with preference for or against RDN. A considerable portion of Veterans with difficult-to-control hypertension at an urban VA Medical Center expressed a preference for RDN if their blood pressure were to be uncontrolled or if recommended by their doctor. These survey results should be considered in shared decision-making discussions for hypertension management in this population.

Performance and Safety of the Medical Device Ialuxid Gel in the Treatment of Mild-Moderate Acne Vulgaris: An Open-Label, Noncomparative Multicentre Interventional Clinical Trial.

Medical literature shows there is no ideal treatment for acne, but topical therapies like benzoyl peroxide, retinoids, and antibiotics have proven to improve mild-moderate cases. Replacing benzoyl peroxide (potentially irritating) with hydrogen peroxide has already been suggested in the medical literature. We investigated a medical device, a proprietary combination of hyaluronic acid, hydrogen peroxide, and glycine in mild-moderate acne vulgaris. Patients of both sexes between ≥ 18 and ≤ 45 years old, with a Global Acne Grading System score ≤ 30, were included. Exclusion criteria were dermal systemic or infectious diseases; allergy to the tested product; pregnant or lactating women; treatment for acne 30 days before baseline; and previous facial aesthetic surgery. Forty patients were treated for 8 weeks several times a day with the tested product and visited at baseline, week 2, week 4, and week 8. Outcomes were decreasing the total number of lesions and the Global Acne Grading System Severity Score, Investigator Global Assessment of Performance with photographs evaluation in blind, Dermatology Life Quality Index, and the Treatment Satisfaction Questionnaire. Adverse events were collected for safety. A 2-fold decrease in the number of lesions at the final visit (-56.3%, p < 0.001). The remaining outcomes evidenced a statistically significant reduction at the final visit. Only 8 adverse events (all mild and related to the tested device) were reported. Results and optimal safety demonstrate that the tested product has a clinical benefit and could be associated with retinoids, as first choice for mild to moderate acne. Clinicaltrial.gov as NCT05345093.

Evaluation of additional resources and stories within therapist-assisted internet-delivered cognitive behaviour therapy for alcohol misuse.

Evaluation of additional resources and stories within therapist-assisted internet-delivered cognitive behaviour therapy for alcohol misuse.